MRNA cancer shot shows promise in early trial
NCT ID NCT07587879
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new mRNA-based immunotherapy called PMC2129G12 in 60 adults with advanced solid tumors that have not responded to standard treatments. The therapy is injected directly into tumors to help the body's immune T cells attack cancer cells. The main goals are to check safety, find the right dose, and see early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-LNP immunotherapy (PMC2129G12)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that are resistant to standard therapies.
What could go wrong
This is an early-phase trial with only 60 participants, so safety and effectiveness are not yet proven. There may be side effects, and the treatment may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IntraAb Inc.
Richmond, California, 94806, United States